Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) Short Interest Up 186.9% in July

Vallon Pharmaceuticals, Inc. (NASDAQ:VLONGet Rating) was the target of a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 140,300 shares, an increase of 186.9% from the June 30th total of 48,900 shares. Approximately 2.9% of the company’s shares are sold short. Based on an average daily volume of 3,340,000 shares, the short-interest ratio is presently 0.0 days.

Vallon Pharmaceuticals Trading Down 6.9 %

NASDAQ:VLON opened at $0.40 on Friday. Vallon Pharmaceuticals has a 1-year low of $0.34 and a 1-year high of $3.45. The firm has a market capitalization of $2.74 million, a price-to-earnings ratio of -0.29 and a beta of -0.86. The business’s 50-day moving average price is $0.54 and its two-hundred day moving average price is $2.73.

Vallon Pharmaceuticals (NASDAQ:VLONGet Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.17). Sell-side analysts predict that Vallon Pharmaceuticals will post -0.99 earnings per share for the current year.

Hedge Funds Weigh In On Vallon Pharmaceuticals

A hedge fund recently bought a new stake in Vallon Pharmaceuticals stock. Laidlaw Wealth Management LLC acquired a new position in shares of Vallon Pharmaceuticals, Inc. (NASDAQ:VLONGet Rating) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 20,200 shares of the company’s stock, valued at approximately $121,000. Laidlaw Wealth Management LLC owned 0.30% of Vallon Pharmaceuticals at the end of the most recent quarter. 5.55% of the stock is currently owned by hedge funds and other institutional investors.

About Vallon Pharmaceuticals

(Get Rating)

Vallon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy.

See Also

Receive News & Ratings for Vallon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vallon Pharmaceuticals and related companies with's FREE daily email newsletter.